ES2140336A1 - Non-virulent mutants of Brucella abortus. - Google Patents
Non-virulent mutants of Brucella abortus.Info
- Publication number
- ES2140336A1 ES2140336A1 ES009800043A ES9800043A ES2140336A1 ES 2140336 A1 ES2140336 A1 ES 2140336A1 ES 009800043 A ES009800043 A ES 009800043A ES 9800043 A ES9800043 A ES 9800043A ES 2140336 A1 ES2140336 A1 ES 2140336A1
- Authority
- ES
- Spain
- Prior art keywords
- mutants
- brucella abortus
- bvrr
- brucella
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Non-virulent mutants of Brucella abortus. A description is given of stable point mutants obtained by insertion of the transposon Tn5 in the genes of Brucella abortus bvrR and bvrS, a two-component transduction-regulating system. The mutants are selected for their sensitivity to bactericidal cationic peptides and surface-active agents. Said peptides keep the smooth characteristics of their lipopolysaccharide, but are totally avirulent in the murine model. Mutant strains of Brucella abortus are obtained, specifically the strain 2.13 (NCTC 13091) with an insertion in the gene bvrR and the strain 65.21 (NCTC 13092) with an insertion in the gene bvrR, both mutants derived from the virulent parental strain Brucella abortus 2308. The natural host of Brucella abortus is cattle, although it can also infect other types of livestock and even man. These mutants can therefore be used as vaccines against brucellosis both in humans and in animals. Moreover, because of the adjuvant capacity of Brucella they can also be used as antigen-presenting recombinant vaccines.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES9800043A ES2140336B1 (en) | 1998-01-13 | 1998-01-13 | NON-VIRULENT MUTANTS OF BRUCELLA ABORTUS. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES9800043A ES2140336B1 (en) | 1998-01-13 | 1998-01-13 | NON-VIRULENT MUTANTS OF BRUCELLA ABORTUS. |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2140336A1 true ES2140336A1 (en) | 2000-02-16 |
ES2140336B1 ES2140336B1 (en) | 2000-10-16 |
Family
ID=8302367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES9800043A Expired - Lifetime ES2140336B1 (en) | 1998-01-13 | 1998-01-13 | NON-VIRULENT MUTANTS OF BRUCELLA ABORTUS. |
Country Status (1)
Country | Link |
---|---|
ES (1) | ES2140336B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7364745B2 (en) * | 2004-02-06 | 2008-04-29 | Virginia Tech Intellectual Properties, Inc. | Development of a live, attenuated, recombinant vaccine for Brucellosis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993016728A1 (en) * | 1992-02-25 | 1993-09-02 | The Texas A & M University System | Improved vaccin against brucella abortus |
-
1998
- 1998-01-13 ES ES9800043A patent/ES2140336B1/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993016728A1 (en) * | 1992-02-25 | 1993-09-02 | The Texas A & M University System | Improved vaccin against brucella abortus |
Non-Patent Citations (7)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7364745B2 (en) * | 2004-02-06 | 2008-04-29 | Virginia Tech Intellectual Properties, Inc. | Development of a live, attenuated, recombinant vaccine for Brucellosis |
Also Published As
Publication number | Publication date |
---|---|
ES2140336B1 (en) | 2000-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Heithoff et al. | Salmonella DNA adenine methylase mutants confer cross-protective immunity | |
Marchetti et al. | Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant | |
Ugalde et al. | Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine | |
IL141623A0 (en) | Method of dna vaccination | |
HUT70986A (en) | Vaccines against aujeszky`s disease and other animal diseases containing pseudorabies virus mutants | |
ITFI920052A1 (en) | PROTEIN EXTRACTED FROM HELICOBACTER PYLORI CYTOTOXIC STRAINS, GENE THAT EXPRESSES IT, USE OF PROTEIN AS VACCINE OR DIAGNOSTIC. | |
WO1996015241A3 (en) | A polynucleotide tuberculosis vaccine | |
PL344593A1 (en) | Attenuated mutants of salmonella | |
DE69333028D1 (en) | DELETION MUTANTS AS VACCINES AGAINST CHOLERA | |
AU4195897A (en) | Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof | |
Baron et al. | Introduction of Shigella flexneri 2a type and group antigen genes into oral typhoid vaccine strain Salmonella typhi Ty21a | |
PL343246A1 (en) | Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines | |
Fuller et al. | A genetically-defined riboflavin auxotroph of Actinobacillus pleuropneumoniae as a live attenuated vaccine | |
TR200002974T2 (en) | Live vaccine against brucellosis | |
ES2140336A1 (en) | Non-virulent mutants of Brucella abortus. | |
Temprano et al. | Potential use of a Yersinia ruckeri O1 auxotrophic aroA mutant as a live attenuated vaccine | |
DE69333751D1 (en) | NON-DISTRIBUTING LIVING HERPESVIRUSVAKZIN | |
Bloom | New approaches to vaccine development | |
AP9901666A0 (en) | Leishmania vaccine. | |
Saito et al. | Complement-Mediated Killing ofPorphyromonas gingivalis381 by the Immunoglobulin G Induced by Recombinant 40-kDa Outer Membrane Protein | |
BR0013093A (en) | Streptomyces avermitilis gene that regulates the ratio of avermectins b2: b1 | |
FR2809960B1 (en) | ADJUVANT COMPOSITION OF THE IMMUNE RESPONSE COMPRISING FHA PROTEIN OR A FRAGMENT OF FHA PROTEIN IN FREE FORM, AND IMMUNOGENIC OR VACCINE COMPOSITION CONTAINING SUCH ADJUVANT COMPOSITION | |
RU97118243A (en) | VACCINE AGAINST BRAZEL CATTLE | |
EP1502602A3 (en) | Methods for therapeutic vaccination | |
AR031370A1 (en) | DOUBLE MUTANT CEPA OF BRUCELLA ABORTUS, PROCESS FOR THEIR PREPARATION, VACCINE, KIT FOR IMMUNIZATION AGAINST BRUCELLOSIS AND DIFFERENTIATION BETWEEN VACCINATED AND INFECTED ANIMALS, AND USE OF THE CEPA FOR THE PREPARATION OF A VACCINE TO PREVENT BRUCELOSIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EC2A | Search report published |
Date of ref document: 20000216 Kind code of ref document: A1 Effective date: 20000216 |
|
FA2A | Application withdrawn |
Effective date: 20031120 |